Literature DB >> 2515961

Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.

P Dellamonica1, E Bernard, H Etesse, R Garraffo, H B Drugeon.   

Abstract

From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7). The length of treatment ranged from 3 to 6 months; follow-up examinations were performed up until July 1988. The infecting bacterial strains (19 Staphylococcus aureus, 2 Staphylococcus epidermidis, 10 Escherichia coli, 8 Pseudomonas aeruginosa) were all sensitive to the quinolone prescribed. Twenty-nine of the 38 evaluable patients had a satisfactory outcome at follow-up examinations 14 to 48 months after the end of treatment. Fourteen of the 21 patients with gram-positive bacterial infections responded satisfactorily, as did 15 of the 17 patients infected by gram-negative bacteria. Nine cases of failure were observed (2 for pefloxacin, 4 for ofloxacin, 3 for ciprofloxacin). The infecting bacteria were Staphylococcus aureus in six cases (3 on ofloxacin, 3 on ciprofloxacin). The infecting bacteria were Staphylococcus aureus in six cases (3 on ofloxacin, 3 on ciprofloxacin), and Staphylococcus epidermidis (ofloxacin), Escherichia coli (pefloxacin), and Pseudomonas aeruginosa (pefloxacin) in one case each. In all these cases, local conditions (presence of a foreign body in 5 cases, sequestra in 3, and post-radiotherapy necrosis in 1) could have been responsible for treatment failure. Tolerance was good; adverse effects observed in the pefloxacin and ofloxacin groups disappeared after treatment was ended. Bone levels varied but were always superior to the MIC for the pathogen. In view of the satisfactory results, the possibility of oral administration, and the good tolerance, these quinolones should be considered as alternative agents for the treatment of chronic osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515961     DOI: 10.1007/bf01975163

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Ofloxacin therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; K Niederriter
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

2.  Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin.

Authors:  R Garraffo; P Dellamonica; E Bernard; H Etesse; P Lapalus
Journal:  Int J Clin Pharmacol Res       Date:  1989

3.  The diffusion of pefloxacin into bone and the treatment of osteomyelitis.

Authors:  P Dellamonica; E Bernard; H Etesse; R Garraffo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis.

Authors:  A G Gristina; J W Costerton
Journal:  J Bone Joint Surg Am       Date:  1985-02       Impact factor: 5.284

5.  High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids.

Authors:  G Montay; Y Blain; F Roquet; A Le Hir
Journal:  J Chromatogr       Date:  1983-02-11

6.  [Bone infections: treatment by ofloxacin. Apropos of 10 cases].

Authors:  E Bernard; H Etesse; R Garraffo; F Giaume; P Dellamonica
Journal:  Pathol Biol (Paris)       Date:  1987-05

Review 7.  New quinolones in the treatment of joint and bone infections.

Authors:  N Desplaces; J F Acar
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

8.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 9.  Lessons learned from animal models of osteomyelitis.

Authors:  C W Norden
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

10.  Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Shinners
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

View more
  8 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 3.  Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

4.  Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience.

Authors:  Thierry Rod-Fleury; Nathalie Dunkel; Mathieu Assal; Peter Rohner; Phedon Tahintzi; Louis Bernard; Pierre Hoffmeyer; Daniel Lew; Ilker Uçkay
Journal:  Int Orthop       Date:  2011-02-12       Impact factor: 3.075

Review 5.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 6.  Diagnosis and management of osteomyelitis. Decision analytic and pharmacoeconomic considerations.

Authors:  M Tavakoli; P Davey; B A Clift; H T Davies
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

7.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics.

Authors:  R F Lucht; A Fresard; P Berthelot; F Farizon; G Aubert; G Dorche; G Bousquet
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.